SCHEMBL1350652

SCHEMBL1350652

CC(=O)Cc1ccc(Br)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 1/20 0.44
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK1 P28482 2/20 0.41
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP3A4 P08684 1/20 0.38
HTT P42858 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29899638 0.83 GRIK1 (0.46) PYCR1MGAMGAASIMGAM2
SCHEMBL473923 0.83 GRIK1 (0.46) PYCR1MGAMGAASIMGAM2
SCHEMBL2951923 0.81 PYCR1 (0.41) PYCR1ALDH1A1MGAMGAASI
SCHEMBL157921 0.81 IDO1 (0.50) MAPK1GAATDP1CYP3A4CYP1A2
SCHEMBL29712851 0.81 IDO1 (0.50) MAPK1GAATDP1CYP3A4CYP1A2
SCHEMBL29536923 0.81 HPGD (0.46) PYCR1ALDH1A1TSHRMEN1KMT2A
SCHEMBL590168 0.81 HPGD (0.46) PYCR1ALDH1A1TSHRMEN1KMT2A
SCHEMBL1922484 0.79 MAPT (0.43) PYCR1ALDH1A1MEN1KMT2AMAPK1
SCHEMBL28065665 0.79 HSD17B10 (0.45) CYP3A4
SCHEMBL15658116 0.79 MAPT (0.46) MAPK1GAAMAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063085-B2 Substituted hydantoins HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
CN-101896469-A Substituted hydantoins as MEK kinase inhibitors HOFFMANN LA ROCHE 2010-11-24 CN disclosed
EP-2234982-A1 SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-10-06 EP disclosed
US-20090170920-A1 SUBSTITUTED HYDANTOINS CHEN SHAOQING 2009-07-02 US disclosed
WO-2009080523-A1 SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170920-A1 SUBSTITUTED HYDANTOINS HNMT, HRH3, BRAF PYCR1 2278/4885ALDH1A1 963/4885TSHR 3695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.